Aug 12 |
Adaptimmune Reports Q2 2024 Financial and Business Updates
|
Aug 9 |
Adaptimmune Q2 2024 Earnings Preview
|
Aug 9 |
Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval
|
Aug 5 |
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
|
Aug 2 |
Agilent gets FDA approval for Tecelra companion diagnostic
|
Aug 2 |
Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma
|
Aug 2 |
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
|
Aug 2 |
Adaptimmune granted FDA accelerated nod for lead asset
|
Aug 2 |
First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer
|
Aug 2 |
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
|